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Abstract Positron emission tomography (PET) is a neuroim-
aging method that offers insights into the molecular function-
ing of a human brain. It has been widely used to study meta-
bolic and neurotransmitter abnormalities in people with epi-
lepsy. This article reviews the development of several PET
radioligands and their application in studying the molecular
mechanisms of epilepsy. Over the last decade, tracers binding
to serotonin and γ-aminobutyric acid (GABA) receptors have
been used to delineate the location of the epileptic focus. PET
studies have examined the role of opioids, cannabinoids, ace-
tylcholine, and dopamine in modulating neuronal hyperexcit-
ability and seizure termination. In vivo analyses of drug trans-
porters, e.g., P-glycoprotein, have increased our understand-
ing of pharmacoresistance that could inform new therapeutic
strategies. Finally, PETexperiments targeting neuroinflamma-
tion and glutamate receptors might guide the development of
novel biomarkers of epileptogenesis.
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Introduction
Positron emission tomography (PET) is one of the first neu-
roimaging techniques that offered unprecedented insights into
the molecular functioning of a living human brain. It involves
the injection of a positron-emitting radioligand (tracer) and the
detection of coincident gamma waves within a scanner. The
resulting image represents the spatial distribution of the tracer
within the brain.
The 1980s saw the first major implementation of PET in
epilepsy after the development of [18F]fluorodeoxyglucose
(FDG) to measure local brain glucose metabolism [1]. It was
soon recognized that focal interictal hypometabolism correlat-
ed with the localization of the epileptic focus, and the method
was widely implemented in presurgical epilepsy evaluation
[2]. Although FDG remains the workhorse radioligand used
in clinical PET imaging, the relevance of FDGPET has slowly
diminished after the advent of high-resolution magnetic reso-
nance tomography (MRI).
The last decade brought a gradual shift to the development
of receptor-specific ligands that would reveal the in vivo neu-
rochemistry of the epileptic brain. Only few tracers have dem-
onstrated acceptable brain penetration, low-nonspecific bind-
ing, high affinity, and target selectivity to progress into clinical
studies (Table 1). This review highlights the latest major
trends, focusing on PET ligands, which have been used in
vivo in people with epilepsy.
γ-Aminobutyric Acid
Since the late 1990s, a large number of PET studies have
described the use of [11C]flumazenil PET in epilepsy. This
radioligand binds to the benzodiazepine site on the γ-
aminobutyric acid (GABAA) receptor complex and has shown
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promising results in the localization and lateralization of the
epileptic focus [3]. Its binding is reduced in hippocampal scle-
rosis and vascular lesios but can be elevated in areas of
dysgenesis.
An interesting finding has recently been obtained with
[11C]flumazenil PET in a mixed group of nonlesional focal
epilepsy patients. Increased seizure frequency was inversely
correlated with uptake in the frontal piriform cortex [4]. This
result is particularly intriguing, because it was independent of
the site of seizure onset and has been reproduced with EEG-
fMRI and morphometric MRI [4, 5]. Similarly, a crucial epi-
leptogenic area has been described in the prepiriform cortex of
rats and monkey and termed Barea tempestas^ [6].
Nevertheless, the tracer has not seen wide application in clin-
ical routine, mainly due to its short half-life. The recent devel-
opment of an [18F] alternative might overcome these restric-
tions [7].
Glutamate
Glutamate is the main excitatory neurotransmitter of the cen-
tral nervous system and is released shortly before and during
epileptic seizures [8].
The N-methyl-D-asparate (NMDA) glutamate receptor is
not only involved in long-term potentiation and learning but
has also been implicated in excitotoxic neuronal damage and
epileptogenesis [9, 10]. Multiple attempts of developing suit-
able PET ligands for imaging NMDA receptors in epilepsy
failed [6]. Experiments in temporal lobe epilepsy (TLE) with
these tracers, e.g., with [11C]-labeled ketamine, usually
showed reduced tracer uptake, possibly reflecting either re-
duced NMDA receptor density, reduced perfusion, or focal
atrophy [11].
[18F]GE-179 PET
We developed [18F]GE-179, which binds to the phency-
clidine site within the NMDA ion channel pore, thus in-
dicating the activated state of the receptor [12]. In a pilot
study, eight epilepsy patients not taking antidepressants
had a significantly increased global radioligand binding
and four had focally increased signal compared to con-
trols suggesting increased NMDA receptor activation
(Fig. 1). This could point to ongoing epileptogenesis in
the group of refractory epilepsy patients [13••]. The most
surprising finding was a markedly decreased global bind-
ing in three epilepsy patients taking antidepressants,
which fell below that of healthy controls. The potential
influence of antidepressants and, possibly, depression on
activation of NMDA receptors warrants further research.
Multidrug transporters
Around one third of epilepsy patients are resistant to treatment
with antiepileptic drugs (AEDs). In these patients,
pharmacoresistance is not limited to a single drug but affects
drugs acting through diverse mechanisms. Multidrug efflux
transporters such as P-glycoprotein might limit intracellular
AED concentration by pumping them from the cell and thus
contribute to drug resistance [14]. Pharmacoresistant epilepsy
was associated with a genotype leading to increased expres-
sion of P-glycoprotein [15], and increased P-glycoprotein ex-
pression has been observed in hippocampal tissue of refracto-
ry epilepsy patients and in rat epilepsy models [16, 17].
[11C]verapamil PET
To study the contribution of P-glycoprotein to pharma
coresistance in vivo, an experimental PET protocol in-
volving a radiolabeled P-glycoprotein substrate,
[11C]verapamil, and partial, half-maximum P-glycoprotein
blockage with tariquidar has been proposed [14]. The
brain uptake of [11C]verapamil would correlate with the
magnitude of P-glycoprotein action at the blood–brain
barrier. Studies in healthy controls confirmed a uniform
Table 1 Overview of radioligands recently used in epilepsy
Group Target Radioligand
GABA GABAA receptor [
11C]flumazenil-PET
[18F]flumazenil-PET
Glutamate NMDA receptor [18F]GE-179
Drug transporters P-glycoprotein [11C]verapamil
Inflammation TSPO [11C]PBR28
[18F]PBR111
[11C](R)-PK11195
Serotonin,
inflammation
Tryptophan
metabolism
α-[11C]methyl-L-
tryptophan
Serotonin 5-HT1A receptor [
18F]MPPF
[11C]WAY-100635
[18F]FCWAY
Serotonin transporter [11C]DASB
Dopamine Presynaptic dopamine [18F]fluoro-L-DOPA
D2/D3 receptor [
18F]fallypride
D1 receptor [
11C]SCH23390
Dopamine transporter [11C]PE2I
Cannabinoids CB1 receptor [
18F]MK-9470
[11C]MePPEP
Opioids μ, δ and κ opioid
receptors
[11C]diprenorphine
μ opioid receptors [11C]carfentanil
δ opioid receptors [11C]methylnaltrindole
Acetylcholine Nicotinic ACh receptor [18F]fluoro-A-85380
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distribution of P-glycoprotein activity throughout the
brain without regional differences [18, 19]. A pilot project
in seven epilepsy patients found a trend for lower
[11C]verapamil influx constants, indicating increased P-
glycoprotein function, in the temporal cortex ipsilateral
to the epileptic focus [20]. Although these results were
obtained in a small sample and failed to reach signifi-
cance, they informed further evaluation of the tracer in
14 drug refractory epilepsy patients, 8 seizure-free pa-
tients, and 13 healthy controls [21••]. Pharmacoresistant
patients had a lower baseline influx rate constant (K1)
corresponding to a higher P-glycoprotein activity. These
results were significant in the bilateral hippocampus, ipsi-
lateral amygdala, fusiform gyrus, inferior temporal gyrus,
and middle temporal gyrus. Seizure frequency was posi-
tively correlated with P-glycoprotein activity in the hip-
pocampus and on a whole brain level. The findings of
[11C]verapamil PET were validated in ex vivo specimen
of five patients who underwent epilepsy surgery.
Equivalent results were externally reproduced in a subse-
quent study of 11 epilepsy patients [22].
A follow-up [11C]verapamil project analyzed P-
glycoprotein activity in seven patients undergoing epilepsy
surgery [23]. Increased P-glycoprotein function before sur-
gery and a decrease postoperatively were associated with op-
timal surgical outcome. The results also indicated that P-
glycoprotein expression responded dynamically to therapeutic
procedures or changes in seizure frequency.
These studies provide intriguing evidence for an involve-
ment of multidrug efflux transporters in pharmacoresistant
epilepsy. If confirmed, [11C]verapamil PET could be used to
identify patients with P-glycoprotein overactivity who might
benefit from novel treatment strategies aimed at inhibiting or
modulating P-glycoprotein activity [21••]. The main limita-
tion is, however, that the authors could not distinguish wheth-
er P-glycoprotein overactivity was a cause or consequence of
increased seizure frequency [24]. Another difficulty arose
from high uptake in the choroid plexus, which complicates
quantification of PET tracer uptake in the hippocampus.
This particular effect was used to outline the choroid plexus
using a different P-glycoprotein substrate tracer, [11C]-N-
desmethyl-loperamide, in a PET study assessing translocator
protein (TSPO) binding in the hippocampus [25].
Inflammation
Inflammatory mediators were found in human and rodent ep-
ileptic tissue and it was demonstrated that experimental sei-
zures caused a rapid and pronounced inflammatory reaction
[26–28]. Additionally, some antiepileptic drugs were shown
to have antiinflammatory properties [29].
Fig. 1 [18F]GE-179 PET/MR scan in a 57-year old temporal lobe
epilepsy patient with signal abnormality in left inferior temporal cortex.
a PET/MR fusion image (left) and MR FLAIR sequence (right)
displaying parts of the lesion (empty arrow) and the hippocampus (full
arrow). b Bilateral comparison of time-activity curves (TACs) in the
inferior temporal cortex (above) and the hippocampus (below). Both
visual analysis and TACs show reduced tracer uptake in the lesioned
temporal cortex and slightly increased uptake in the ipsilateral
hippocampus. Hypothetically, the extralesional increase of NMDA-
receptor activation in the ipsilateral hippocampus could point to ongoing
epileptogenesis and prospective studies will be needed to prove this
assumption
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Translocator protein positron emission tomography
Several PET tracers have been developed to target neuroin-
flammation [30]. The most commonly used radioligands are
[11C]PK11195 and [11C]PBR28 that bind to TSPO, a marker
of activatedmicroglia [26]. The concentration of TSPO is very
low in healthy brain tissue; however, a marked increase can be
observed in experimental models inducing neuroinflamma-
tion in the form of microglial activation [31, 32]. This increase
can be reliably measured with TSPO PET tracers [31, 32]. In
rat models of epileptogenesis, increased TSPO expression
pointing to neuroinflammation can be demonstrated with
PET [28]. The inflammatory process peaks 2 weeks after ini-
tial status epilepticus but limbic activation of microglia per-
sists into the chronic phase [26].
The first human investigations with TSPO PET were per-
formed in single subjects or small case series with presumed
inflammatory epileptic encephalopathies. In an elegant study,
unilaterally increased TSPO expression has been demonstrat-
ed with 11C-PK11195 PET in two patients with histologically
confirmed Rasmussen’s encephalitis, substantiating the role of
neuroinflammation in this syndrome [33]. Similarly, increased
tracer binding has been demonstrated in a case with seizures
due to cerebral vasculitis and in another patient with an epi-
leptic encephalitis of unknown etiology [34, 35].
Two recent well-powered studies in temporal lobe epi-
lepsy showed increased TSPO radioligand uptake,
pointing to activation of microglia, in temporal regions
ipsilateral to the epileptic focus and, to a lesser extent,
in the ipsilateral thalamus and contralateral temporal lobe
[36••, 37]. However, concordance of increased TSPO PET
signal with the ictal-EEG onset zone has not been evalu-
ated and the role of this technique as a diagnostic local-
izing tool is uncertain. Nevertheless, these in vivo find-
ings give support to a local neuroinflammation in human
epileptic cortex. Although the causal role of brain inflam-
mation in generating seizures still needs to be confirmed,
these observations might provide a rationale for
antiinflammatory treatment in some epilepsy patients.
Serotonin
The influence of serotonin (5-HT) on hyperexcitability
has been studied for decades. Several animal models dem-
onstrated that elevating extracellular serotonin levels in-
hibits seizures, mainly acting through the 5-HT1A receptor
subtype [38]. Conversely, increased levels of serotonin
metabolites were found in resected epileptic tissue [39].
The interest in serotonin has led to the development of
several suitable PET tracers that study three different as-
pects of cerebral serotonin function.
α-[11C]methyl-L-tryptophan positron emission
tomography
Originally, increased uptake of α-[11C]methyl-L-tryptophan
([11C]AMT) was thought to reflect increased serotonin syn-
thesis. The downside of this approach is that serotonin metab-
olism might be disturbed in disease and the findings are diffi-
cult to interpret in a pathophysiological context [40].
Additionally, recent evidence in patients with tuberous sclero-
sis complex (TSC) points to an increased tryptophan metabo-
lism via the kynurenine pathway in the presence of neuroin-
flammation, leading to the production of proconvulsants [40].
Hence, [11C]AMT PET might also reflect the degree of in-
flammation in neuronal tissue.
The differentiation of epileptogenic and non-epileptogenic
tubers was extensively examined with [11C]AMT PET and
increased tracer binding was consistently demonstrated in tu-
bers that colocalized with ictal EEG findings [41–43]. A re-
cently published large series of 191 TSC patients demonstrat-
ed excellent agreement of [11C]AMT PET with ictal EEG
findings [44••]. Moreover, [11C]AMT PETsupplied localizing
information in more than half of patients with inconclusive
EEG. The results were independent of underlying TSC muta-
tion. A smaller series of 12 TSC patients demonstrated low
sensitivity (12 %) but high specificity (100 %) of [11C]AMT
PET in the prediction of epileptogenic tubers [45•]. Although
this series is relatively small, it is one of few [11C]AMT PET
studies performed outside of Detroit, providing valuable data
for external validation of this tracer.
[11C]AMT PET has also been applied to intractable child-
hood epilepsy of other causes [46, 47]. Again, sensitivity for
correct localizing information was low, but nearly perfect
specificity surpassed that of FDG PET. However, the limiting
factor for the clinical use of this promising tracer is the diffi-
cult synthesis and short half-life (20 min). Production is cur-
rently restricted to a few dedicated centers worldwide, which
severely impacts the application of these findings in clinical
practice.
5-HT1A Receptor Ligands and Tracer for Serotonin
Transporter
The density of 5-HT1A receptors has been measured with sev-
eral PET tracers that differ in their pharmacological properties
(Table 1). [18F]MPPF is a selective antagonist of 5-HT1Awith
an affinity close to that of serotonin and is, hence, sensitive to
endogenous serotonin variations. Conversely, [11C]WAY-
100635 and [18F]FCWAY are high-affinity agonists of 5-
HT1A and they do not compete with endogenous serotonin
[48]. Finally, [11C]DASB can measure serotonin transporter
5-HTT availability, the main terminator of synaptic serotonin
effect [49•].
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Decrease of 5-HT1A receptor density ipsilateral to seizure
focus is a consistent finding in TLE. Many PET studies using
[18F]MPPF, [11C]WAY-100635, and [18F]FCWAY have dem-
onstrated similar results despite using different methodical
approaches [50–56]. The decreases were more pronounced
in the hippocampus and in areas involved in seizure genera-
tion [52, 55]. These findings fit well with the concept of a
proconvulsive effect of serotonin depletion.
The use of 5-HT1A receptor PET in presurgical epilepsy
evaluation has only been tested in small patient samples. 5-
HT1A receptor PET showed decreased temporal binding in
more than 80 % of these cases and all pathological decreases
were congruent with the lateralization of the ictal onset on
EEG [54, 57]. All patients with lateralizing [18F]MPPF PET
became seizure-free after surgery [57]. These results suggest a
higher specificity than FDG PET; however, they remain to be
reproduced in larger patient samples. The sensitivity of 5-
HT1A receptor PET can be further improved by comparing
tracer binding between both cerebral hemispheres using asym-
metry indices. This increases the sensitivity to above 90 %
with a specificity of 88 % [58].
Some studies have reported HT1A abnormalities beyond
the temporal lobe, describing decreased [18F]FCWAY binding
in the insular cortex and anterior cingulate [51, 52]. Such
changes in the limbic areas were significantly more common
in epilepsy patients with concomitant depression compared to
those without mood disturbances[51, 53]. Also, the magnitude
of hippocampal binding inversely correlated with depressive
symptoms [59]. These results suggest a common
pathomechanism of epilepsy and comorbid depression due
to a decrease of serotonin receptors that extends beyond the
temporal lobe and affects limbic structures.
A seemingly contradictory finding was demonstrated using
[18F]MPPF PET, showing increased uptake in insula and ra-
phe nuclei of depressed epilepsy patients [60]. However, this
increased bindingmost likely reflects a decreased extracellular
serotonin concentration in epilepsy patients with depression
resulting in increased 5-HTT availability.
A recent study examined serotonin transporter 5-HTT
function using [11C]DASB PET in 13 TLE patients and 16
controls [49•]. There were no regional differences in 5-HTT
function between patients and controls. However, epilepsy
patients with history of depression had a relatively reduced
5-HTT activity in the ipsilateral insula compared to those
without depression. A reduced transporter activity would de-
crease serotonin reuptake and might represent a compensation
mechanism to increase extracellular serotonin concentration.
Insular 5-HTT activity correlated with 5-HT1A receptor den-
sity measured with [18F]FCWAY-PET, indicating that a reduc-
tion of 5-HT1A receptors may be associated with decreased
reuptake of serotonin. However, this study creates more
questions than it answers. It remains unclear why epilepsy
patients without depression do not show reduced 5-HTT
function and why depressed patients develop mood disorders
despite these compensatory mechanisms. The results need to
be interpreted with caution especially because contra-
dictory findings were reported in patients with major
depression [61].
Dopamine
BThe role of dopamine in epilepsy is intriguing, complex, and
unresolved^ [62]. Initial input came from experimental data
suggesting that dopaminergic neurons in the striatum and
substantia nigra were involved in seizure termination [63,
64]. These dopamine-rich nigrostriatal areas are thought to
modulate thalamocortical projections to regions involved in
epilepsy syndromes [62].
Within the past decade, a number of PET studies demon-
strated an abnormal subcortical dopaminergic system in epi-
lepsy. Almost unequivocally, they found a bilaterally reduced
dopaminergic function within the basal ganglia. The utiliza-
tion of several radioligands demonstrated different aspects of
dopaminergic dysregulation (Table 1): a presynaptic dopami-
nergic deficit using [18F]fluoro-L-DOPA [65–67], decreased
D2/D3-receptor binding using [
18F]fallypride [68–71], de-
creased D1-receptor binding using [
11C]SCH23390 [72], and
reduced dopamine transporter activity with [11C]PE2I
[73–75]. These authors investigated a variety of epilepsy syn-
dromes including temporal lobe epilepsy, juvenile myoclonic
epilepsy, idiopathic generalized epilepsy, autosomal dominant
nocturnal frontal lobe epilepsy (ADNFLE), and ring chromo-
some 20 syndrome. Most authors found abnormalities in the
striatum, whereas changes in the midbrain (i.e., substantia
nigra) were reported in juvenile myoclonic epilepsy [73–75].
Although it is difficult to assess dopaminergic binding outside
the basal ganglia, two studies described decreased uptake of
the epileptogenic zone of patients with temporal lobe epilepsy
[68, 71].
The diversity of methodical approaches and patient
populations underlines the robustness of these results.
However, the detection of dopaminergic abnormalities in-
dependent of the underlying type or pathology of epilepsy
suggests that these alterations are a nonspecific reaction to
seizures [76].
Taken together, an altered dopaminergic system is
commonly seen in epilepsy and might act to impair ter-
mination of seizures. Also, the findings highlight the im-
portance of subcortical structures in epilepsy. However,
the basal ganglia likely represent only the tip of the ice-
berg within a more widespread dopamine dysregulation.
Nevertheless, it is difficult to ascertain significant
extrastriatal changes with PET because cortical binding
of dopamine is generally low [62, 76].
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Cannabinoids
Most PET ligand development in this group has focused on
cannabinoid receptor 1 (CB1), the major cannabinoid receptor
in the central nervous system. Several lines of evidence indi-
cate that CB1 has anticonvulsant properties that mainly rely on
the induction and modulation of protective neuronal
mechanisms [77, 78]. A downregulation of CB1 during
epileptogenesis might impair these mechanisms and facilitate
seizures [79, 80]. However, experimental research is not entirely
conclusive as others have reported that activation of CB1 recep-
tors might be proepileptogenic as CB1 antagonists prevented the
development of epilepsy [81].
Goffin et al. recently examined the activation of the
endocannabinoid system in temporal lobe epilepsy with the
CB1 radioligand [
18F]MK-9470 [82]. They found an increased
uptake in the temporal lobe ipsilateral to the epileptic cortex and
a bilateral decrease in insular CB1 binding. However, the
authors could not differentiate whether increased CB1 availabil-
ity in the epileptic cortex was an abnormal proconvulsive or a
protective anticonvulsive phenomenon.
Quantification of CB1 receptor availability using a different
radioligand, [11C]MePPEP, recently showed good to excellent
reproducibility [83] with investigation of CB1 receptor-
mediated neurotransmission in epilepsy currently under way.
Opioids
Increased release of endogenous opioids has previously been
demonstrated during provoked absences and reading-induced
seizures [84, 85]. These findings have underlined the potential
Table 2 Main findings of recent PET studies in epilepsy
Group Target Main findings in epilepsy patients Author’s interpretation
GABA GABAA receptor Inverse correlation of seizure frequency with uptake
in the frontal piriform cortex in patients with
different sites of seizure onset [4].
The prepiriform cortex might represent a common
epileptogenic area independent of the localization
of seizure onset.
Glutamate NMDA receptor Increased global uptake in patients not on
antidepressants. [13••]
Global increase of NMDA receptor activation might
reflect ongoing epileptogenesis.
Multidrug
transporters
P-glycoprotein Increased P-glycoprotein activity in
pharmacoresistant patients, particularly in
mesiotemporal areas [21••, 22]
Increased P-glycoprotein activity could contribute to
multidrug resistance by reducing the intracellular
concentration of antiepileptic drugs.
Inflammation TSPO Increased uptake in ipsilateral temporal lobe and, to a
lesser extent, in ipsilateral thalamus and
contralateral temporal lobe. [36••, 37]
Increased TSPO expression points to activation of
microglia and an inflammatory reaction in epilepsy
patients that could induce epileptogenesis.
Serotonin,
inflammation
Tryptophan
metabolism
Increased uptake in epileptic vs. non-epileptic brain
tubers in TSC. Increased uptake in the epileptic
focus of children with intractable epilepsy. Low
sensitivity but high specificity of these findings
[44••, 45•, 46, 47]
[11C]AMT-PET adds valuable information on the
location of the epileptic focus. It might reflect
increased tryptophan metabolism that indicates the
local production of proconvulsants.
Serotonin 5-HT1A receptor Reduced uptake ipsilaterally to seizure focus,
particularly in the hippocampus. Decreased uptake
in insular cortex and anterior cingulate in
depressed epilepsy patients [50–59]
Adds lateralizing information with higher specificity
than FDG-PET. Awidespread reduction of
serotonin receptors extending beyond the temporal
lobemight indicate a pathomechanism of comorbid
depression.
Serotonin transporter Reduced uptake in ipsilateral insula in epilepsy
patients with depression [49•]
Decreased serotonin reuptake might represent a
compensatory mechanism for low serotonin levels
in comorbid depression.
Dopamine Presynaptic dopamine,
D1/D2/D3 receptor,
dopamine
transporter
Bilaterally reduced uptake in basal ganglia,
particularly striatum and substantia nigra [65–75]
An altered dopaminergic neurotransmission might
impair termination of seizures.
Cannabinoids CB1 receptor Increased uptake in ipsilateral temporal lobe;
decreased uptake in bilateral insula [82]
Supports dysregulation of cannabinoids in epilepsy
that could represent a pro or anticonvulsive
phenomenon.
Opioids μ, δ. and κ opioid
receptors
Reduced radioligand uptake during absence and
reading-induced seizures. Increased uptake 8 h
after spontaneous seizures [84–87]
Opioid release during seizures might contribute to
seizure termination. This is likely followed by an
early interictal overexpression of opioid receptors.
Acetylcholine Nicotinic ACh
receptor
Increased uptake in epithalamus, ventral
mesencephalon, and cerebellum in ADNFLE
patients. Decreased uptake in prefrontal cortex [90]
Thalamic and mesencephalic findings may indicate a
unique mechanism of nocturnal seizures in
ADNFLE. Reduced prefrontal receptor density
could be due to neuronal loss.
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role of opioids in the termination of epileptic seizures.
[11C]diprenorphine
A recent study investigated opioid receptor binding using
[11C]diprenorphine PET after spontaneous seizures [86].
Hammers et al. scanned nine refractory temporal lobe ep-
ilepsy patients within hours after spontaneous seizures
and rescanned them during the later interictal phase.
After a median postictal interval of 8 h, increased binding
was found in the ipsilateral temporal pole, fusiform gyrus,
and, after correction for the partial volume effect, also in
the parahippocampal gyrus [87]. There was a negative
correlation of ligand uptake with the postictal interval,
pointing to an early increase in binding with a gradual
return to normal.
These findings might either indicate an increased expression
of opioid receptors, a reduced endogenous opioid tone or both.
In context with previous research, the authors favored the first
explanation. The most likely sequence after spontaneous sei-
zures starts with a release of endogenous opioids leading to
decreased [11C]diprenorphine binding [84, 85]. This is followed
by a rapid recovery of available receptors and an overshoot in
receptor expression, depicted as increased binding after 8 h on
PET [86, 87]. Finally, there is a gradual return to normal or low-
normal levels during the interictal phase.
Acetylcholine
ADNFLE is an uncommon familial epilepsy syndrome
associated with hypermotor seizures occurring during
sleep. Two causative genes have been described, most
likely leading to a gain of function of the α4β2 subtype
of the nicotinic acetylcholine receptor (nAChR) [88, 89].
Picard et al. examined eight ADNFLE patients using
PET with [18F]fluoro-A-85380, a high affinity agonist at
the α4β2 nAChR [90]. Increased tracer uptake was dem-
onstrated in the epithalamus, ventral mesencephalon, and
cerebellum, whereas decreased binding was found in the
right dorsolateral prefrontal region. The mesencephalic
and thalamic increases point toward an overactivated cho-
linergic pathway ascending from the brainstem. These
findings are particularly interesting in the context of a
sleep disorder and might indicate a unique pathogenesis
of nocturnal seizures. Conversely, decreased receptor den-
sity in the prefrontal region could be due to neuronal loss
as part of the frontal lobe epilepsy.
However, some questions remain unanswered. It remains
unknown whether the observed changes are a hallmark of
ADNFLE or a non-specific consequence of seizures.
Moreover, although the authors demonstrated spatial changes
in receptor density, the functional consequences of the muta-
tion on nAChR activity remain unclear.
Conclusions
PET studies have successfully demonstrated a number of mo-
lecular functional abnormalities in epilepsy (Table 2). These
insights have not only increased our understanding of the un-
derlying mechanisms of seizures but will also improve the
diagnostic evaluation of MRI negative patients. Increasing
efforts are being put into translating the novel results into the
development of new therapeutics. These will specifically tar-
get the neurotransmitters and molecular mechanisms demon-
strated in PET studies.
A central challenge will be to tackle the problem of
epileptogenesis. The long latent period between an initial in-
sult and the subsequent development of seizures offers plenty
of time for diagnostic and therapeutic interventions [91]. PET
might play an important role as a biomarker by revealing the
molecular processes involved in the development of
epileptogenesis.
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